248 related articles for article (PubMed ID: 21060307)
21. Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma.
He M; Aisner S; Benevenia J; Patterson F; Harrison LE; Hameed M
Pathol Res Pract; 2009; 205(6):386-94. PubMed ID: 19186005
[TBL] [Abstract][Full Text] [Related]
22. Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma.
Przybyl J; Spans L; Ganjoo K; Bui N; Mohler D; Norton J; Poultsides G; Debiec-Rychter M; van de Rijn M
PLoS One; 2022; 17(1):e0262272. PubMed ID: 34986184
[TBL] [Abstract][Full Text] [Related]
23. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
[TBL] [Abstract][Full Text] [Related]
24. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.
Asano N; Yoshida A; Mitani S; Kobayashi E; Shiotani B; Komiyama M; Fujimoto H; Chuman H; Morioka H; Matsumoto M; Nakamura M; Kubo T; Kato M; Kohno T; Kawai A; Kondo T; Ichikawa H
Oncotarget; 2017 Feb; 8(8):12941-12952. PubMed ID: 28099935
[TBL] [Abstract][Full Text] [Related]
25. Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.
Hwang JA; Yang HM; Hong DP; Joo SY; Choi YL; Park JH; Lazar AJ; Pollock RE; Lev D; Kim SJ
Oncotarget; 2014 Oct; 5(19):9065-78. PubMed ID: 25238053
[TBL] [Abstract][Full Text] [Related]
26. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
[TBL] [Abstract][Full Text] [Related]
27. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
[TBL] [Abstract][Full Text] [Related]
28.
Casadei L; Calore F; Braggio DA; Zewdu A; Deshmukh AA; Fadda P; Lopez G; Wabitsch M; Song C; Leight JL; Grignol VP; Lev D; Croce CM; Pollock RE
Cancer Res; 2019 Oct; 79(19):4911-4922. PubMed ID: 31387924
[TBL] [Abstract][Full Text] [Related]
29. GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases.
Sharma AE; Dickson M; Singer S; Hameed MR; Agaram NP
Mod Pathol; 2024 Apr; 37(6):100494. PubMed ID: 38621503
[TBL] [Abstract][Full Text] [Related]
30. Degree of
Bill KLJ; Seligson ND; Hays JL; Awasthi A; Demoret B; Stets CW; Duggan MC; Bupathi M; Brock GN; Millis SZ; Shakya R; Timmers CD; Wakely PE; Pollock RE; Chen JL
Oncologist; 2019 Jul; 24(7):989-996. PubMed ID: 31019022
[TBL] [Abstract][Full Text] [Related]
31. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 Jan; 34(1):260-270. PubMed ID: 32949334
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.
Yamashita K; Kohashi K; Yamada Y; Akatsuka S; Ikuta K; Nishida Y; Toyokuni S; Oda Y
Genes Chromosomes Cancer; 2021 Jan; 60(1):26-37. PubMed ID: 33111425
[TBL] [Abstract][Full Text] [Related]
33. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
Kyriazoglou A; Pagkali A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Moutafi M; Gavrielatou N; Anastasiou M; Boulouta A; Pantazopoulos A; Giannakakou M; Digklia A; Psyrri A
Cancer Treat Rev; 2024 Apr; 125():102716. PubMed ID: 38492514
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
[TBL] [Abstract][Full Text] [Related]
35. Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers.
Cassinelli G; Pasquali S; Lanzi C
Front Oncol; 2022; 12():965261. PubMed ID: 36119484
[TBL] [Abstract][Full Text] [Related]
36. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Akiyama T; Iwata S; Sugaya J; Yoshida A; Kawai A; Kondo T
Hum Cell; 2022 May; 35(3):936-943. PubMed ID: 35292923
[TBL] [Abstract][Full Text] [Related]
37. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
[TBL] [Abstract][Full Text] [Related]
38. MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas.
Laroche A; Chaire V; Algeo MP; Karanian M; Fourneaux B; Italiano A
Oncotarget; 2017 Aug; 8(33):53968-53977. PubMed ID: 28903316
[TBL] [Abstract][Full Text] [Related]
39. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
[TBL] [Abstract][Full Text] [Related]
40. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.
Thirasastr P; Lin H; Amini B; Wang WL; Cloutier JM; Nassif EF; Keung EZ; Roland CL; Feig B; Araujo D; Benjamin RS; Conley AP; Livingston JA; Ludwig J; Patel S; Ratan R; Ravi V; Zarzour MA; Zhou X; Somaiah N
Cancer Med; 2023 Feb; 12(4):4282-4293. PubMed ID: 36151848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]